ASCO 2021: Inducible T-Cell Co-Stimulatory Receptor Agonist, Feladilimab, Alone and in Combination With Pembrolizumab: Results From INDUCE-1 Urothelial Carcinoma Expansion Cohorts

(UroToday.com) Inducible T-cell co-stimulatory expression is induced on T-cells following T-cell receptor activation and previous studies have demonstrated that inducible T-cell co-stimulation is highly expressed in urothelial carcinoma across all stages of disease.